Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients

International Journal of Antimicrobial Agents

Volumn 30, Issue 4, 2007, Pages 352-355

  Ikawa, Kazuro ^a   Morikawa, Norifumi ^a   Matsuda, Shusaku ^a   Ikeda, Kayo ^a   Ohge, Hiroki ^a   Takesue, Yoshio ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cefozopran; Peritoneal fluid; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFOZOPRAN;

ABDOMINAL SURGERY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PERITONEAL FLUID; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; VENOUS BLOOD;

ABDOMEN; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASCITIC FLUID; BLOOD CHEMICAL ANALYSIS; CEPHALOSPORINS; COMPUTER SIMULATION; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 34548411255     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.06.001     Document Type: Article

References (15)

1. Kobayashi H., Moritono S., and Hara K. Significant role of new cephem antibiotics: focused on cefozopran. Jpn J Antibiot 50 (1997) 807-820 [in Japanese]
2. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin Infect Dis 27 (1998) 10-22
3. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17 (2003) 479-501
4. Burmaster D.E., and Anderson P.D. Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments. Risk Anal 14 (1994) 477-481
5. Drusano G.L., Preston S.L., Hardalo C., et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 45 (2001) 13-22
6. Mouton J.W., Dudley M.N., Cars O., Derendorf H., and Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55 (2005) 601-607
7. Craig W.A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22 (1995) 89-96
8. Drusano G.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 36 Suppl. 1 (2003) S42-S50
9. Borner K., Borner E., and Lode H. Determination of a new cephalosporin, SCE-2787, in serum and urine by high-performance liquid chromatography. J Chromatogr 615 (1993) 174-179
10. Ikeda K., Ikawa K., Ikeda A., Nishikawa Y., and Morikawa N. A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 844 (2006) 148-152
11. Yamaoka K., Tanigawara Y., Nakagawa T., and Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4 (1981) 879-885
12. Chen M., Nafziger A.N., Drusano G.L., Ma L., and Bertino Jr. J.S. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 50 (2006) 1222-1227
13. Goldstein E.J., and Snydman D.R. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 53 Suppl. 2 (2004) ii29-ii36
14. Rossi F., Baquero F., Hsueh P.R., et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 58 (2006) 205-210
15. Yamamoto T., Adachi Y., Nagamine Y., Suwa M., and Nanno T. Clinical phase I study of cefozopran. Shinryou To Shinyaku (Treat New Med) 30 (1993) 281-304